Patents by Inventor Manali Mukherjee

Manali Mukherjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-DFS70 Autoantibodies and methods of attenuating formation of nets
    Publication number: 20240383971
    Abstract: A method of attenuating the formation of neutrophil extracellular traps (NETs) in a mammal is provided comprising administering to the mammal a therapeutically effective amount of DFS70 autoantibody, a functionally equivalent variant thereof or nucleic acid encoding DFS70 antibody.
    Type: Application
    Filed: May 18, 2023
    Publication date: November 21, 2024
    Inventor: Manali Mukherjee
  • DNA APTAMERS FOR EOSINOPHIL PEROXIDASE DETECTION
    Publication number: 20230295635
    Abstract: This disclosure relates to DNA aptamers that bind eosinophil peroxidase, including uses thereof, such as in eosinophil peroxidase detection assays. Also provided is a method for detecting the presence of eosinophil peroxidase in a sample, using the DNA aptamers that bind eosinophil peroxidase. Further provided is a kit for detecting the presence of eosinophil peroxidase in a sample, using the DNA aptamers that bind eosinophil peroxidase.
    Type: Application
    Filed: October 14, 2022
    Publication date: September 21, 2023
    Inventors: John D. Brennan, Monsur Ali, Michael Wolfe, Dawn White, Manali Mukherjee, Parameswaran Nair, Alfredo Capretta
  • Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
    Patent number: 11224653
    Abstract: Disclosed herein are methods of treating severe glucocorticoid-dependent eosinophilic asthma in a subject whose asthma has been inadequately controlled with subcutaneously-administered mepolizumab. Also provided are methods of predicting responsiveness to anti-IL-5 antibody treatment in a subject having severe glucocorticoid-dependent eosinophilic asthma.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: January 18, 2022
    Assignee: Cephalon, Inc.
    Inventors: Parameswaran Nair, Manali Mukherjee
  • TREATMENT STRATEGY FOR NON-RESPONDERS TO 100MG SUBCUTANEOUS MEPOLIZUMAB
    Publication number: 20190062421
    Abstract: Disclosed herein are methods of treating severe glucocorticoid-dependent eosinophilic asthma in a subject whose asthma has been inadequately controlled with subcutaneously-administered mepolizumab. Also provided are methods of predicting responsiveness to anti-IL-5 antibody treatment in a subject having severe glucocorticoid-dependent eosinophilic asthma.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 28, 2019
    Inventors: Parameswaran Nair, Manali Mukherjee